Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.39 |
| ▸ | ADH1B | P00325 | 2/20 | 0.34 |
| ▸ | ADH1C | P00326 | 2/20 | 0.34 |
| ▸ | ADH1A | P07327 | 2/20 | 0.34 |
| ▸ | ADH7 | P40394 | 2/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167887 | 0.98 | EPHX1 (0.42) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL29918589 | 0.98 | EPHX1 (0.42) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL11922809 | 0.93 | TSHR (0.36) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL7831036 | 0.87 | DPP4 (0.31) | — | |
| SCHEMBL9152291 | 0.87 | EPHX1 (0.38) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL9286517 | 0.82 | TDP1 (0.34) | TSHR | |
| SCHEMBL29321716 | 0.82 | ALDH1A1 (0.39) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL18780547 | 0.80 | EPHX1 (0.42) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL9942667 | 0.80 | EPHX1 (0.42) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL841225 | 0.80 | TSHR (0.46) | TSHRALDH1A1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103443171-B | Polyethylene film | 伊奎斯塔化学有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | TSHR 454/4885ALDH1A1 873/4885EPHX1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.